Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Tetracenomycin Aglycones Primarily Inhibit Cell Growth and Proliferation in Mammalian Cancer Cell Lines

  • Kyah Birdsall
  • , Adwowa B.S. Brako
  • , Courtney Brown
  • , Kendall Paige
  • , Alexis West
  • , Nora Schwartz
  • , Jacob Hecht
  • , Katelyn V. Brown
  • , Jon S. Thorson
  • , Khaled A. Shaaban
  • , S. Eric Nybo

Producción científica: Articlerevisión exhaustiva

Resumen

Tetracenomycins are anticancer polyketides that arrest cancer cell proliferation via binding to the large mammalian ribosomal subunit near the polypeptide exit channel. The tetracenomycins are natural products that many members of the actinomycete family produce. The first goal of this study was to improve the biosynthesis of tetracenomycin analogs via metabolic engineering. The second goal was to probe more deeply into the antiproliferative activity of tetracenomycin aglycones. The tetracenomycins were assessed via several assays, including cell viability assays, clonogenic assays, and flow cytometry apoptosis assays. The data suggest that tetracenomycins C and X inhibit cell proliferation and arrest cell growth, supporting their cytostatic action mechanism. In addition, tetracenomycins C and X induced degeneration of 3D spheroid cultures and exhibited concentration-dependent inhibition of cell survival and colony formation in clonogenic assays. This work demonstrates that tetracenomycins act mainly as cytostatic rather than apoptotic agents.

Idioma originalEnglish
Número de artículo11985
PublicaciónApplied Sciences (Switzerland)
Volumen15
N.º22
DOI
EstadoPublished - nov 2025

Nota bibliográfica

Publisher Copyright:
© 2025 by the authors.

Financiación

Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award No. R15CA252830 (to S.E.N.) and the National Science Foundation under Grant No. ENG-2015951 (to S.E.N.). This work was also supported by National Institutes of Health grant R37 AI052218 (J.S.T.), the Center of Biomedical Research Excellence (COBRE) for Translational Chemical Biology (CTCB, NIH P20 GM130456), the National Institute of Food and Agriculture (USDA-NIFA-CBGP, Grant No. 2023-38821-39584; K.A.S. and J.S.T), the University of Kentucky College of Pharmacy, the University of Kentucky Markey Cancer Center and the National Center for Advancing Translational Sciences (UL1TR000117 and UL1TR001998).

FinanciadoresNúmero del financiador
University of Kentucky
University of Kentucky Markey Comprehensive Cancer Center
Center of Biomedical Research Excellence
National Childhood Cancer Registry – National Cancer Institute
National Institutes of Health (NIH)P20 GM130456, R15CA252830
US Department of Agriculture National Institute of Food and Agriculture, Agriculture and Food Research Initiative2023-38821-39584
National Science Foundation Arctic Social Science ProgramR37 AI052218, ENG-2015951
National Center for Advancing Translational Sciences (NCATS)UL1TR001998, UL1TR000117

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • General Materials Science
    • Instrumentation
    • General Engineering
    • Process Chemistry and Technology
    • Computer Science Applications
    • Fluid Flow and Transfer Processes

    Huella

    Profundice en los temas de investigación de 'Tetracenomycin Aglycones Primarily Inhibit Cell Growth and Proliferation in Mammalian Cancer Cell Lines'. En conjunto forman una huella única.

    Citar esto